Showing 4141-4150 of 6036 results for "".
- FDA Approves Genentech’s Vabysmo Prefilled Syringe for AMD, DME, and RVOhttps://modernod.com/news/genentechs-vabysmo-prefilled-syringe-approved-by-fda-for-amd-dme-and-rvo/2482342/Genentech announced FDA approval of Vabysmo (faricimab-svoa) 6.0 mg single-dose prefilled syringe (PFS) for use in the treatment of wet age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema after retinal vein occlusion (RVO). The company advised that Vabysmo
- Notal Vision Announces Results From Prospective Trial Using Home-Based OCThttps://modernod.com/news/notal-vision-announces-results-from-prospective-trial-using-home-based-oct/2482331/Notal Vision announced the results from the first prospective clinical trial using home-based optical coherence tomography (OCT) to manage wet age-related macular degeneration (AMD) patients in an investigational setting. The results, which were published in Retina, demonstrated a
- FDA Clears Alcon's Unity Vitreoretinal-Cataract System and Standalone Cataract Systemhttps://modernod.com/news/fda-clears-alcons-unity-vitreoretinal-cataract-system-and-unity-standalone-cataract-system/2482329/Alcon announced that its Unity Vitreoretinal Cataract System (VCS) and Unity Cataract System (CS) have received FDA 510(k) clearance. The new devices are the first to be introduced from Alcon’s Unity portfolio and represent Alcon's next generation of e
- Ocugen Doses First Patient in Phase 3 Clinical Trial for OCU400 Gene Therapy for RPhttps://modernod.com/news/ocugen-doses-first-patient-in-phase-3-clinical-trial-for-ocu400-gene-therapy-for-retinitis-pigmentosa/2482326/Ocugen announced that the first patient has been dosed in its phase 3 liMeliGhT clinical trial for OCU400, a modifier gene therapy product candidate being developed for retinitis pigmentosa (RP). “Each clinical milestone achieved by OCU400 brings us closer to providing a one-
- Neurotech Receives Priority Review of BLA for NT-501 as a Treatment for Macular Telangiectasia Type 2 (MacTel)https://modernod.com/news/neurotech-receives-priority-review-of-biologics-license-application-bla-for-nt-501-as-a-treatment-for-macular-telangiectasia-type-2-mactel/2482324/The FDA has granted priority review of Neurotech Pharmaceuticals's biologic license application (BLA) for NT-501 (revakinagene taroretcel), an investigational encapsulated cell therapy for the treatment of Macular Telangiectasia Type 2 (MacTel). The designation m
- J&J's Nipocalimab Significantly Improves Sjögren’s Disease Activity in a Phase 2 Studyhttps://modernod.com/news/jjs-nipocalimab-significantly-improves-sjogrens-disease-activity-in-a-phase-2-study/2482323/Johnson & Johnson announced that patients treated with nipocalimab demonstrated statistically significant (P=0.002) and clinically meaningful improvement in ClinESSDAIa score versus placebo at 24 weeks compared to baseline (primary endpoint) in the phase 2 DAHLIAS dose-rang
- Beacon Therapeutics Treats First Patient in VISTA Trial of AGTC-501 for XLRPhttps://modernod.com/news/beacon-therapeutics-treats-first-patient-in-vista-registrational-trial-for-agtc-501/2482319/Beacon Therapeutics announced the treatment of the first patient in its registrational VISTA clinical trial with its lead asset, AGTC-501 (laruparetigene zovaparvovec). VISTA is a global randomized, controlled, masked, multicenter pivotal study evaluating the efficacy, safety, and
- Skye Fails Phase 2 Glaucoma Trial; Shifts Focus to Obesityhttps://modernod.com/news/skye-fails-phase-2-glaucoma-trial-shifts-focus-to-obesity/2482317/Skye Bioscience announced that its phase 2a clinical trial of SBI-100 ophthalmic emulsion in patients with primary open-angle glaucoma or ocular hypertension did not meet its primary endpoint for lowering IOP. As a result, Skye intends to discontinue clinical development and spendi
- Geoff Tabin, MD, Co-Founder of Global NGO HCP Cureblindness, Steps Into New Rolehttps://modernod.com/news/geoff-tabin-md-co-founder-of-global-ngo-hcp-cureblindness-steps-into-new-role/2482314/Effective immediately, Geoff Tabin, MD, will step down as Board Chair of the global nonprofit HCP Cureblindness (Himalayan Cataract Project), but will maintain an active role on the Board as Medical Director. Long-time HCP volunteer and Board Member, Matt Oliva, MD, will lead HCP into its excitin
- Galimedix Establishes SAB in Advance of Phase 2 Study of GAL-101 for Dry AMDhttps://modernod.com/news/galimedix-therapeutics-establishes-scientific-advisory-board-in-advance-of-phase-2-study-of-gal-101-for-dry-amd/2482313/Galimedix Therapeutics has formed a Scientific Advisory Board (SAB) to provide advice and direction to the company for the development of its compound GAL-101 for the treatment of dry age-related macular degeneration (AMD). The SAB consists of retina experts from both clinical prac